OYST - Oyster Point Pharma Non-GAAP EPS of -$1.61 misses by $0.23 revenue of $6.59M beats by $6.29M
Oyster Point Pharma press release (NASDAQ:OYST): Q4 GAAP EPS of -$1.61 misses by $0.23. Revenue of $6.59M beats by $6.29M. As of December 31, 2021, cash, cash equivalents, and restricted cash were $193.4 million, compared to $184.2 million as of September 30, 2021.
For further details see:
Oyster Point Pharma Non-GAAP EPS of -$1.61 misses by $0.23, revenue of $6.59M beats by $6.29M